false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
2021 Annual Global Meeting: Virtual
Master Session: Ovarian Cancer
Master Session: Ovarian Cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video content discussed the definition of high-risk patients in ovarian cancer, which can vary depending on factors such as tumor grade, stage, histology, and adverse factors. The goal is to identify patients who may benefit from more aggressive treatment approaches. The importance of biomarkers in guiding the use of PARP inhibitor therapy was emphasized, with a focus on identifying subsets of patients who are most likely to benefit from this treatment. The challenge of making all ovarian cancers responsive to PARP inhibitors was discussed, highlighting the need for prognostic and predictive biomarkers. The session also touched upon surgical management techniques to achieve complete resection and improve outcomes. Biomarkers, particularly BRCA mutation status, were identified as important predictors of PARP inhibitor benefit, and ongoing research is exploring other biomarkers and the need for validation and standardization. Issues of equity were also addressed, emphasizing the importance of ensuring access to care for all women. Future directions in the field include the identification of novel biomarkers, the use of whole genome sequencing signatures, and the implementation of artificial intelligence. The session concluded with a discussion on rare ovarian tumor types and the need for clinical trials to evaluate targeted therapies based on specific biomarkers. Overall, the video provided valuable insights into current challenges and advancements in the management of ovarian cancer and emphasized the need for further research and collaboration to improve patient outcomes.
Keywords
high-risk patients
ovarian cancer
tumor grade
stage
histology
adverse factors
aggressive treatment
biomarkers
PARP inhibitor therapy
surgical management
complete resection
BRCA mutation status
prognostic biomarkers
predictive biomarkers
equity in access
Contact
education@igcs.org
for assistance.
×